# Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

> **NCT05653531** · NA · WITHDRAWN · sponsor: **Centre Hospitalier Universitaire, Amiens**

## Conditions studied

- Immune Checkpoint Inhibitor
- Lung Cancer
- Liver Biomarkers
- Transaminases

## Interventions

- **OTHER:** Blood sample

## Key facts

- **NCT ID:** NCT05653531
- **Lead sponsor:** Centre Hospitalier Universitaire, Amiens
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-10-25
- **Primary completion:** 2023-04-01
- **Final completion:** 2023-07-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no participants enrolled
- **Last updated:** 2023-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05653531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05653531, "Clinical Significance of Hepatic Biomarkers in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05653531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*